Nocion Therapeutics, a clinical-stage biopharmaceutical company, has raised $62 million in Series B funding.
 
Nocion is developing small molecule, permanently charged sodium channel blockers (CSCBs), called nocions, that selectively silence activated nociceptors for the treatment of serious conditions involving cough, itch, and pain. Proceeds from the financing will be used to evaluate the lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study in Chronic Cough patients.
 
The Series B financing was led by Arkin Bio Capital and Monograph Capital, with participation from additional new investors as well as existing investors Canaan Partners, F-Prime Capital, Mass General Brigham Ventures, Mission BioCapital and Osage University Partners. With this financing, Nocion has raised $122 million since the company was founded in 2018.
 
“We are grateful to our new and existing investors for their commitment to our lead program in this challenging disease,” said Dr. Richard Batycky, Chief Executive Officer of Nocion. “This financing will enable us to evaluate Taplucanium in patients suffering from Chronic Cough. We will also be able to conduct additional toxicology and product development activities with an eye towards being ready for Phase 3 clinical trials.”
 
In conjunction with the Series B financing, Pini Orbach, Ph.D., of Arkin Bio Capital and Freddie Dear of Monograph Capital will join Nocion’s Board of Directors.